Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Margenza (margetuximab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GC Biopharma, MacroGenics, ZAI Lab

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (388)

lapatinib (106)

neratinib (102)

trastuzumab-pkrb (24)

poziotinib (17)

mobocertinib (11)

trastuzumab-dttb (11)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Zercepac (trastuzumab biosimilar) (7)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

BAY 2927088 (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HER2-TAC γδ T (0)

HER2Bi-armed ATC (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
FCGR3A 158F	HER2 Positive Breast Cancer	FCGR3A 158F	HER2 Positive Breast Cancer	margetuximab Sensitive: B - Late Trials margetuximab Sensitive : B	margetuximab Sensitive: B - Late Trials margetuximab Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab + MGD013 Sensitive: C2 – Inclusion Criteria margetuximab + MGD013 Sensitive : C2	margetuximab + MGD013 Sensitive: C2 – Inclusion Criteria margetuximab + MGD013 Sensitive : C2
HER-2 positive	Gastric Adenocarcinoma	HER-2 positive	Gastric Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab Sensitive : C2	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab Sensitive : C2
HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab Sensitive : C2	pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria pembrolizumab + margetuximab Sensitive : C2
HER-2 amplification + PD-L1 expression	Gastric Cancer	HER-2 amplification + PD-L1 expression	Gastric Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
HER-2 expression	Gastrointestinal Cancer	HER-2 expression	Gastrointestinal Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
PD-L1 expression + HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression + HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
PD-L1 expression + HER-2 overexpression	Gastric Cancer	PD-L1 expression + HER-2 overexpression	Gastric Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
HER-2 amplification + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 amplification + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	HER-2 amplification	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
HER-2 amplification	Gastric Cancer	HER-2 amplification	Gastric Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	margetuximab + MGD013 Sensitive: C3 – Early Trials margetuximab + MGD013 Sensitive : C3	margetuximab + MGD013 Sensitive: C3 – Early Trials margetuximab + MGD013 Sensitive : C3
HER-2 positive	Gastroesophageal Cancer	HER-2 positive	Gastroesophageal Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3	pembrolizumab + margetuximab Sensitive: C3 – Early Trials pembrolizumab + margetuximab Sensitive : C3
HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	margetuximab + retifanlimab-dlwr Sensitive: C3 – Early Trials margetuximab + retifanlimab-dlwr Sensitive : C3	margetuximab + retifanlimab-dlwr Sensitive: C3 – Early Trials margetuximab + retifanlimab-dlwr Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	margetuximab Sensitive: C4 – Case Studies margetuximab Sensitive : C4	margetuximab Sensitive: C4 – Case Studies margetuximab Sensitive : C4